Active, not recruitingInterventionalPhase 2Updated Sep 8, 2025
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) | NCT04155541 | Trialant
CompletedObservationalUpdated Jun 11, 2026
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Special Investigation for Vizimpro Tablets
ClinicalTrials.gov ID
NCT04155541
Lead Sponsor
PfizerINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
40Actual
Last Update Posted
Jun 11, 2026Actual
Start Date
Jan 24, 2020Actual
Primary Completion Date
Apr 25, 2025Actual
Completion Date
Apr 25, 2025Actual
Official Title
Special Investigation for Vizimpro Tablets
Brief Summary
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
EGFR Mutation-positive Inoperable or Reccrent NSCLC
dacomitinib hydrate
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)